Biotech Stocks: Cellulite Treatment Market Projected to Have Strong Growth Rate Through 2028

PALM BEACH, Florida: The consumer demand for a solution to cellulite has been growing for years. Cellulite is a cosmetic problem, not a disease process. It affects 85pc to 90pc of all women worldwide and 10pc of men.

A recent article titled Cellulite Treatment Market to Reflect Impressive Growth Rate During 2028 said: Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, and biotech, key markets across the world are facing a massive rise in demand for critical care services (including cellulite) that are pushing global healthcare spending levels to unimaginable limits. The size of the global consumer pool for non-invasive cellulite treatments has been growing at a very strong pace, and it seems to be projected for even more substantial growth in the coming decade. In fact, this yearly increase started back in 2013 when an industry report lamented about the lack of a solution. The report said: No effective treatment currently exists for cellulite; that is, the condition associated with the dimpled appearance of skin, commonly on the thighs and buttocks. According to the American Society for Aesthetic Plastic Surgery, up to 90% of women and 10% of men have cellulite. An effective, long-lasting treatment remains the goal of both researchers and countless patients.

While cellulite isn't harmful, it is a serious cosmetic concern for many people who want to feel better about their appearance and reduce cellulite as much as possible. The methods to remove cellulite are many, but none yet have been supported in medical literature to be effective or potentially usable as a standard practice. Active Healthcare companies in the markets this week include: Soliton, Inc. (NASDAQ: SOLY), G1 Therapeutics, Inc. (NASDAQ: GTHX), Novan, Inc. (NASDAQ: NOVN), Pfizer Inc. (NYSE: PFE), Becton, Dickinson and Company (NYSE: BDX)

Well now, jump forward to the present and notice the vastly increased amount of optimism in an article on the American Academy of Dermatology's (AAD) website, titled Cellulite Treatments: What Really Works. The report says: If cellulite bothers you, you're not alone. Our desire to get rid of — or at least diminish — cellulite has led to many treatment options. With so many treatments out there, it can be hard to know what, if anything, works. To find out, dermatologists have been conducting research studies. You'll be happy to know that the research shows some treatments can make cellulite less noticeable... Here's the lowdown.

Soliton, Inc. (NASDAQ: SOLY) BREAKING NEWS: Soliton, a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (MD Anderson), today announced that its manufacturing partner has delivered the first single-use cartridges capable of delivering the therapy targeting cellulite reduction.

The cartridge attaches to the treatment head and is designed to be used for a single patient cellulite treatment and then replaced. The cartridge is capable of delivering higher-powered acoustic pulses at greater depths than the Company's tattoo removal cartridge, and both cartridges can be used with the same higher-powered pulse generating console, creating a true platform technology with a range of potential uses in the practicioner's office. Neither the cartridge nor the device has been cleared by the FDA.

We are very enthusiastic about the flexibility that our interchangeable treatment heads will bring to the practicioners that partner with us for the treatment of cellulite reduction and tattoo removal, commented Dr. Chris Capelli, President, CEO and co-founder of Soliton. Our therapy will be delivered through single-use cartridges that are designed to be used for one patient treatment. Once our device is cleared by the FDA, we expect to deliver a recurring revenue stream and drive top-line growth for the Company.

Dr. Capelli added: We believe that this recurring revenue model will be readily adopted by the marketplace as other aesthetic technologies have led the way with pay-per-use models. We believe practicioners will be enthusiastic about our technology that, upon FDA clearance, could be used across multiple indications. Read this and more news for SOLY at:
(PRN | 1 year ago)

Like This Article?
Biotech Stocks: Cellulite Treatment Market Projected to Have Strong Growth Rate Through 2028